Document is current
Any future updates will be listed below
-
Authors
Chen, Fangyuan https://orcid.org/0000-0002-9891-4753
Shi, Qingya https://orcid.org/0000-0001-9724-3743
Pei, Fen https://orcid.org/0000-0003-4278-8265
Vogt, Andreas https://orcid.org/0000-0001-6846-9292
Porritt, Rebecca A
Garcia, Gustavo Jr
Gomez, Angela C
Cheng, Mary Hongying
Schurdak, Mark E
Liu, Bing https://orcid.org/0000-0002-7257-2441
Chan, Stephen Y
Arumugaswami, Vaithilingaraja
Stern, Andrew M https://orcid.org/0000-0002-8437-2957
Taylor, D Lansing
Arditi, Moshe https://orcid.org/0000-0001-9042-2909
Bahar, Ivet https://orcid.org/0000-0001-9959-4176
-
Funding
Funding for this research was provided by:
American Heart Association (18EIA33900027)
American Lung Association (ETRA734979)
HHS | National Institutes of Health (P41 GM103712)
HHS | National Institutes of Health (PO1 DK096990)
HHS | National Institutes of Health (RO1 DK117881)
HHS | National Institutes of Health (UG3 DK119973)
HHS | National Institutes of Health (S10 OD028450)
- License Information
-
More Information
Article History
Received: 21 January 2021
Revised: 10 June 2021
Accepted: 11 June 2021
First Online: 2 August 2021
Conflict of interests
: S.Y.C. has served as a consultant for United Therapeutics; and S.Y.C. has held research grants from Actelion and Pfizer. S.Y.C. is a founder, director, and officer in Synhale Therapeutics. The other authors declare no conflict of interests regarding the publication of this paper.
